NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»10/11/2009 [Company watch]
Pfizer Cutbacks Reflect Difficulties Facing Big Pharma

Pfizer announced it would close six out of its 20 R&D facilities around the globe

Pfizer Cutbacks Reflect Difficulties Facing Big Pharma by: ChinaBio Today November 10, Pfizer announced it would close six out of its 20 R&D facilities around the globe as part of its post-Wyeth-acquisition consolidation. Some employees will be transferred to other facilities, while others will be let go. Pfizer did not disclose how many of its R&D staff would be fired, though it said R&D square footage would be reduced by 35%. The company’s Shanghai R&D operation was not affected by the reorganisation. After the changes, Pfizer will have five major R&D centres: Cambridge, Mass.; Groton, Conn.; Pearl River, N.Y.; La Jolla, Calif.; and Sandwich, U.K. There are three additional “research-oriented laboratories” with specialised research capabilities: monoclonal antibody discovery in San Francisco, regenerative medicine in Cambridge, UK, and research and development activities in Shanghai, China. The Shanghai facility was given the least specific mission of the three. Pfizer’s Shanghai operation now has a staff of 345, up from 17 when the facility opened in 2005. Its strategy follows a partnership model that is neither virtual nor completely in-house. In recent months, the company has announced two cooperation agreements, one with Fudan University and the other with the Shanghai Institutes of Biological Sciences. Pfizer says it has spent $150 million on its China R&D operations between 2005 and the first six months of 2009. Pfizer will close its R&D facilities in Princeton, NJ; Chazy, Rouses Point and Plattsburgh, NY; Sanford and Research Triangle Park, NC; and Gosport, Slough/Taplow, UK. It will move some functions from Collegeville, PA; Pearl River, NY; and St. Louis to other locations.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.